Landos Biopharma Inc (DELISTED) (LABP:DL)
22.93
+0.13
(+0.58%)
USD |
NASDAQ |
May 23, 16:00
Landos Biopharma SG&A Expense (Quarterly): 6.144M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 6.144M |
December 31, 2023 | 3.463M |
September 30, 2023 | 2.136M |
June 30, 2023 | 1.976M |
March 31, 2023 | 3.153M |
December 31, 2022 | 3.099M |
September 30, 2022 | 2.967M |
June 30, 2022 | 4.662M |
March 31, 2022 | 4.153M |
Date | Value |
---|---|
December 31, 2021 | 6.952M |
September 30, 2021 | 3.059M |
June 30, 2021 | 2.596M |
March 31, 2021 | 2.646M |
December 31, 2020 | 1.44M |
September 30, 2020 | 1.453M |
June 30, 2020 | 1.365M |
March 31, 2020 | 1.08M |
December 31, 2019 | 0.381M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.381M
Minimum
Dec 2019
6.952M
Maximum
Dec 2021
2.929M
Average
2.806M
Median
SG&A Expense (Quarterly) Benchmarks
AbbVie Inc | 3.377B |
Fusion Pharmaceuticals Inc (DELISTED) | 14.55M |
Masimo Corp | 177.50M |
Kinnate Biopharma Inc (DELISTED) | 5.734M |
Invivyd Inc | 21.09M |